Bank of The West lessened its holdings in McKesson Co. (NYSE:MCK) by 5.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,371 shares of the company’s stock after selling 124 shares during the quarter. Bank of The West’s holdings in McKesson were worth $321,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. CSat Investment Advisory L.P. increased its holdings in McKesson by 19.7% in the 4th quarter. CSat Investment Advisory L.P. now owns 364 shares of the company’s stock valued at $50,000 after buying an additional 60 shares during the period. Penserra Capital Management LLC increased its holdings in McKesson by 55.6% in the 4th quarter. Penserra Capital Management LLC now owns 210 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the period. Jacobi Capital Management LLC increased its holdings in McKesson by 2.5% in the 1st quarter. Jacobi Capital Management LLC now owns 3,412 shares of the company’s stock valued at $461,000 after buying an additional 82 shares during the period. Hi Line Capital Management LLC increased its holdings in McKesson by 0.3% in the 4th quarter. Hi Line Capital Management LLC now owns 35,786 shares of the company’s stock valued at $4,950,000 after buying an additional 90 shares during the period. Finally, EPG Wealth Management LLC increased its holdings in McKesson by 75.2% in the 1st quarter. EPG Wealth Management LLC now owns 233 shares of the company’s stock valued at $32,000 after buying an additional 100 shares during the period. 84.96% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE MCK opened at $145.82 on Friday. The firm’s 50-day simple moving average is $135.93 and its 200 day simple moving average is $142.74. The company has a market cap of $25.90 billion, a price-to-earnings ratio of 28.42, a price-to-earnings-growth ratio of 1.57 and a beta of 0.82. The company has a quick ratio of 0.56, a current ratio of 0.99 and a debt-to-equity ratio of 1.51. McKesson Co. has a 12-month low of $112.60 and a 12-month high of $172.18.
McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.10 by $0.17. The business had revenue of $58.54 billion for the quarter, compared to the consensus estimate of $55.60 billion. McKesson had a net margin of 0.39% and a return on equity of 41.07%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.69 EPS. On average, equities analysts expect that McKesson Co. will post 15.23 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be given a dividend of $0.41 per share. The ex-dividend date is Friday, May 29th. This represents a $1.64 dividend on an annualized basis and a yield of 1.12%. McKesson’s payout ratio is presently 10.97%.
Several brokerages have recently commented on MCK. JPMorgan Chase & Co. boosted their target price on shares of McKesson from $186.00 to $187.00 and gave the company an “overweight” rating in a research note on Wednesday, March 18th. Robert W. Baird upgraded shares of McKesson from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $164.00 to $197.00 in a research note on Friday, February 7th. Barclays reduced their target price on shares of McKesson from $170.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 31st. Guggenheim upgraded shares of McKesson from a “neutral” rating to a “buy” rating in a research note on Friday, March 13th. Finally, ValuEngine downgraded shares of McKesson from a “sell” rating to a “strong sell” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $166.31.
In other McKesson news, CEO Brian S. Tyler sold 4,063 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $135.00, for a total transaction of $548,505.00. Following the transaction, the chief executive officer now directly owns 16,255 shares in the company, valued at approximately $2,194,425. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 8,187 shares of company stock worth $1,064,057. Corporate insiders own 0.88% of the company’s stock.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Article: What are momentum indicators and what do they show?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.